# A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

> **NCT04102618** · EARLY_PHASE1 · TERMINATED · sponsor: **Oncolytics Biotech** · enrollment: 26 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Pelareorep
- **DRUG:** Letrozole
- **DRUG:** Atezolizumab
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04102618
- **Lead sponsor:** Oncolytics Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-29
- **Primary completion:** 2022-04-20
- **Final completion:** 2022-04-20
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.
- **Last updated:** 2022-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04102618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04102618, "A Window-of-opportunity Study of Pelareorep in Early Breast Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04102618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*